Complete Chemotherapeutic Regression of a Non-Metastatic Case of Primary Pure Small Cell Carcinoma of the Prostate

Yahyazadeh, Seyed Hossein; Abadpour, Behrang; Molanaei, Saadat; Jamali, Arsia

doi:10.1159/000338869

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average overall survival (OS) of all patients was 7.29 months. The average OS of the 4 patients who received chemotherapy was 9.75 months (8,12,6, and 13 months), while the average OS of patients who did not receive chemotherapy was 4 months (5, 1, 6 months).…”

Section: Resultsmentioning

confidence: 98%

Pure Small Cell Carcinoma of Prostate: A Report of 8 Cases

Zhang¹,

Ouyang²,

Sun³

et al. 2018

Urol Int

View full text Add to dashboard Cite

Purpose: To describe characteristics of pure small cell carcinoma of prostate (SCCP) and assess the prognostic factors. Patients and Methods: We summarized data of pure SCCP from published studies and ours and made Kaplan-Meier analysis and Cox regression to evaluate prognosis factors. Results: A total of 2,213 patients with prostate cancer was identified, of which eight (0.36%) patients were pure SCCP. The mean age at diagnosis was 61 years old. And there were 2 patients diagnosed at 34 and 50 years old respectively. Symptoms of these patients were similar to patients with prostate adenocarcinoma. Serum prostate specific antigen of 7 patients was at normal level. Five patients received chemotherapy, average overall survival (OS) was 9.75 months; 3 only received conservative treatment, average OS was 4 months. By univariate and multivariate Cox analysis, chemotherapy is an independent predictor of survival. Kaplan-Meier analysis demonstrated that chemotherapy was associated with longer OS. Conclusion: Clinical characteristics, examination and treatment strategy of pure SCCP are very different from prostate adenocarcinoma. According to the data from published studies and from our studies, the average survival of patients receiving chemotherapy is longer than those who received other treatment modalities.

show abstract

Section: Resultsmentioning

confidence: 98%